Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review

October 2021 | 52 pages | ID: N6D75561A1FEN
GlobalData

Abstracts

Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Switzerland, Sweden and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA Key Recent Developments

Sep 16,2021: Newron announces Half-Year 2021 results
Sep 06,2021: Newron receives Fourth Tranche from Financing Agreement with European Investment Bank
Apr 13,2021: Newron announces AGM 2021 result
Mar 16,2021: Newron announces 2020 financial results and provides outlook for 2021
Sep 15,2020: Newron announces half-year 2020 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Newron Pharmaceuticals SpA - Key Facts
Newron Pharmaceuticals SpA - Key Employees
Newron Pharmaceuticals SpA - Key Employee Biographies
Newron Pharmaceuticals SpA - Major Products and Services
Newron Pharmaceuticals SpA - History
Newron Pharmaceuticals SpA - Company Statement
Newron Pharmaceuticals SpA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Newron Pharmaceuticals SpA - Business Description
Newron Pharmaceuticals SpA - Corporate Strategy
Newron Pharmaceuticals SpA - SWOT Analysis
SWOT Analysis - Overview
Newron Pharmaceuticals SpA - Strengths
Newron Pharmaceuticals SpA - Weaknesses
Newron Pharmaceuticals SpA - Opportunities
Newron Pharmaceuticals SpA - Threats
Newron Pharmaceuticals SpA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Newron Pharmaceuticals SpA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 16, 2021: Newron announces Half-Year 2021 results
Sep 06, 2021: Newron receives Fourth Tranche from Financing Agreement with European Investment Bank
Apr 13, 2021: Newron announces AGM 2021 result
Mar 16, 2021: Newron announces 2020 financial results and provides outlook for 2021
Sep 15, 2020: Newron announces half-year 2020 results
Aug 11, 2020: Newron Pharmaceuticals provides clinical and business update
Apr 15, 2020: Newron receives third tranche from financing agreement with European Investment Bank (EIB)
Mar 05, 2020: Newron announces 2019 financial results and provides outlook for 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Newron Pharmaceuticals SpA, Key Facts
Newron Pharmaceuticals SpA, Key Employees
Newron Pharmaceuticals SpA, Key Employee Biographies
Newron Pharmaceuticals SpA, Major Products and Services
Newron Pharmaceuticals SpA, History
Newron Pharmaceuticals SpA, Subsidiaries
Newron Pharmaceuticals SpA, Key Competitors
Newron Pharmaceuticals SpA, Ratios based on current share price
Newron Pharmaceuticals SpA, Annual Ratios
Newron Pharmaceuticals SpA, Annual Ratios (Cont...1)
Newron Pharmaceuticals SpA, Interim Ratios
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Newron Pharmaceuticals SpA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Newron Pharmaceuticals SpA, Performance Chart (2016 - 2020)
Newron Pharmaceuticals SpA, Ratio Charts
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021